NCT04995835View on ClinicalTrials.gov

Cefiderocol PK in Patients on ECMO

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

June 1, 2024

Study Completion Date

September 1, 2024

Conditions
Sepsis
Interventions
DRUG

Cefiderocol

After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol

Trial Locations (2)

10032

Columbia University/New York Presbyterian Hospital, New York

06102

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

Shionogi Inc.

INDUSTRY

lead

Joseph L. Kuti, PharmD

OTHER

NCT04995835 - Cefiderocol PK in Patients on ECMO | Biotech Hunter | Biotech Hunter